Clinical Trial

Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.
Protocol Amendment History 4 changes
notable Trial sites expanded: 10 -> 13 locations 2026-07-11
notable Primary completion pushed: 2027-09 -> 2027-10 2026-07-11
critical Recruitment opened 2026-05-27
notable Trial sites expanded: 2 -> 10 locations 2026-05-27
Trial Details
NCT Number NCT07527650
Lead Sponsor Hanmi Pharmaceutical Company Limited
Conditions Type 2 Diabetes Mellitus, T2DM
Enrollment 180 participants
Start Date 2026-05-18
Primary Completion 2027-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-03